Compare Abbott Laboratories (ABT) vs Transocean Ltd (RIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Transocean Ltd — how do they compare? Abbott Laboratories trades at $95.27 (market cap $166.94B), while Transocean Ltd trades at $5.18 (market cap $5.56B). The key difference: Abbott Laboratories is far larger — about 30× Transocean Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| ABT | RIG | |
|---|---|---|
Market Cap | $166.94B | $5.56B |
Sector | Health | Technology |
52-Week High | $136.62 | $7.58 |
52-Week Low | $82.57 | $2.55 |
Enterprise Value | $193.69B | $10.50B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Transocean Ltd. (RIG) trades at $4.93, down 2.57% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion revenue, though recent contract wins including a $1 billion Equinor deal and the pending Valaris merger aim to strengthen backlog and reduce leverage. Analyst consensus is divided with 39% buy ratings and a $7.00 price target, 42% above current levels.
RIG presents a high-risk opportunity with significant upside potential if operational improvements and merger synergies materialize. Key risks include persistent net losses, oil price volatility, and execution challenges from the Valaris integration. The stock's below-book valuation (P/B 0.56) and strong revenue backlog provide a margin of safety, but investors must weigh the turnaround potential against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
